Global Age-Related Macular Degeneration (AMD) Therapeutics Market Growth (Status and Outlook) 2024-2030
The report requires updating with new data and is sent in 48 hours after order is placed.
According to our LPI (LP Information) latest study, the global Age-Related Macular Degeneration (AMD) Therapeutics market size was valued at US$ 7557.7 million in 2023. With growing demand in downstream market, the Age-Related Macular Degeneration (AMD) Therapeutics is forecast to a readjusted size of US$ 11380 million by 2030 with a CAGR of 6.0% during review period.
The research report highlights the growth potential of the global Age-Related Macular Degeneration (AMD) Therapeutics market. Age-Related Macular Degeneration (AMD) Therapeutics are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Age-Related Macular Degeneration (AMD) Therapeutics. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Age-Related Macular Degeneration (AMD) Therapeutics market.
Age-related macular degeneration is a bilateral ocular condition in which the central area of the retina, known as the macula, is affected.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The report on Age-Related Macular Degeneration (AMD) Therapeutics market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Age-Related Macular Degeneration (AMD) Therapeutics market. It may include historical data, market segmentation by Type (e.g., Wet AMD, Dry AMD), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Age-Related Macular Degeneration (AMD) Therapeutics market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Age-Related Macular Degeneration (AMD) Therapeutics market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Age-Related Macular Degeneration (AMD) Therapeutics industry. This include advancements in Age-Related Macular Degeneration (AMD) Therapeutics technology, Age-Related Macular Degeneration (AMD) Therapeutics new entrants, Age-Related Macular Degeneration (AMD) Therapeutics new investment, and other innovations that are shaping the future of Age-Related Macular Degeneration (AMD) Therapeutics.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Age-Related Macular Degeneration (AMD) Therapeutics market. It includes factors influencing customer ' purchasing decisions, preferences for Age-Related Macular Degeneration (AMD) Therapeutics product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Age-Related Macular Degeneration (AMD) Therapeutics market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Age-Related Macular Degeneration (AMD) Therapeutics market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Age-Related Macular Degeneration (AMD) Therapeutics market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Age-Related Macular Degeneration (AMD) Therapeutics industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Age-Related Macular Degeneration (AMD) Therapeutics market.
Market Segmentation:
Age-Related Macular Degeneration (AMD) Therapeutics market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
According to our LPI (LP Information) latest study, the global Age-Related Macular Degeneration (AMD) Therapeutics market size was valued at US$ 7557.7 million in 2023. With growing demand in downstream market, the Age-Related Macular Degeneration (AMD) Therapeutics is forecast to a readjusted size of US$ 11380 million by 2030 with a CAGR of 6.0% during review period.
The research report highlights the growth potential of the global Age-Related Macular Degeneration (AMD) Therapeutics market. Age-Related Macular Degeneration (AMD) Therapeutics are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Age-Related Macular Degeneration (AMD) Therapeutics. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Age-Related Macular Degeneration (AMD) Therapeutics market.
Age-related macular degeneration is a bilateral ocular condition in which the central area of the retina, known as the macula, is affected.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The report on Age-Related Macular Degeneration (AMD) Therapeutics market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Age-Related Macular Degeneration (AMD) Therapeutics market. It may include historical data, market segmentation by Type (e.g., Wet AMD, Dry AMD), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Age-Related Macular Degeneration (AMD) Therapeutics market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Age-Related Macular Degeneration (AMD) Therapeutics market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Age-Related Macular Degeneration (AMD) Therapeutics industry. This include advancements in Age-Related Macular Degeneration (AMD) Therapeutics technology, Age-Related Macular Degeneration (AMD) Therapeutics new entrants, Age-Related Macular Degeneration (AMD) Therapeutics new investment, and other innovations that are shaping the future of Age-Related Macular Degeneration (AMD) Therapeutics.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Age-Related Macular Degeneration (AMD) Therapeutics market. It includes factors influencing customer ' purchasing decisions, preferences for Age-Related Macular Degeneration (AMD) Therapeutics product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Age-Related Macular Degeneration (AMD) Therapeutics market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Age-Related Macular Degeneration (AMD) Therapeutics market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Age-Related Macular Degeneration (AMD) Therapeutics market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Age-Related Macular Degeneration (AMD) Therapeutics industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Age-Related Macular Degeneration (AMD) Therapeutics market.
Market Segmentation:
Age-Related Macular Degeneration (AMD) Therapeutics market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
- Wet AMD
- Dry AMD
- Hospital
- Clinic
- Research Institute
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Amgen Inc.
- Bausch Health Companies, Inc.
- F. Hoffmann-La Roche Ltd.
- Novartis AG
- Regeneron Pharmaceuticals Inc.
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size 2019-2030
2.1.2 Age-Related Macular Degeneration (AMD) Therapeutics Market Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Age-Related Macular Degeneration (AMD) Therapeutics Segment by Type
2.2.1 Wet AMD
2.2.2 Dry AMD
2.3 Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type
2.3.1 Age-Related Macular Degeneration (AMD) Therapeutics Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size Market Share by Type (2019-2024)
2.4 Age-Related Macular Degeneration (AMD) Therapeutics Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Research Institute
2.4.4 Other
2.5 Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application
2.5.1 Age-Related Macular Degeneration (AMD) Therapeutics Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size Market Share by Application (2019-2024)
3 AGE-RELATED MACULAR DEGENERATION (AMD) THERAPEUTICS MARKET SIZE BY PLAYER
3.1 Age-Related Macular Degeneration (AMD) Therapeutics Market Size Market Share by Players
3.1.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Players (2019-2024)
3.1.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 AGE-RELATED MACULAR DEGENERATION (AMD) THERAPEUTICS BY REGIONS
4.1 Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Regions (2019-2024)
4.2 Americas Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth (2019-2024)
4.3 APAC Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth (2019-2024)
4.4 Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth (2019-2024)
4.5 Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth (2019-2024)
5 AMERICAS
5.1 Americas Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country (2019-2024)
5.2 Americas Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2019-2024)
5.3 Americas Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Region (2019-2024)
6.2 APAC Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2019-2024)
6.3 APAC Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Age-Related Macular Degeneration (AMD) Therapeutics by Country (2019-2024)
7.2 Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2019-2024)
7.3 Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics by Region (2019-2024)
8.2 Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2019-2024)
8.3 Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) THERAPEUTICS MARKET FORECAST
10.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Forecast by Regions (2025-2030)
10.1.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Forecast by Regions (2025-2030)
10.1.2 Americas Age-Related Macular Degeneration (AMD) Therapeutics Forecast
10.1.3 APAC Age-Related Macular Degeneration (AMD) Therapeutics Forecast
10.1.4 Europe Age-Related Macular Degeneration (AMD) Therapeutics Forecast
10.1.5 Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Forecast
10.2 Americas Age-Related Macular Degeneration (AMD) Therapeutics Forecast by Country (2025-2030)
10.2.1 United States Age-Related Macular Degeneration (AMD) Therapeutics Market Forecast
10.2.2 Canada Age-Related Macular Degeneration (AMD) Therapeutics Market Forecast
10.2.3 Mexico Age-Related Macular Degeneration (AMD) Therapeutics Market Forecast
10.2.4 Brazil Age-Related Macular Degeneration (AMD) Therapeutics Market Forecast
10.3 APAC Age-Related Macular Degeneration (AMD) Therapeutics Forecast by Region (2025-2030)
10.3.1 China Age-Related Macular Degeneration (AMD) Therapeutics Market Forecast
10.3.2 Japan Age-Related Macular Degeneration (AMD) Therapeutics Market Forecast
10.3.3 Korea Age-Related Macular Degeneration (AMD) Therapeutics Market Forecast
10.3.4 Southeast Asia Age-Related Macular Degeneration (AMD) Therapeutics Market Forecast
10.3.5 India Age-Related Macular Degeneration (AMD) Therapeutics Market Forecast
10.3.6 Australia Age-Related Macular Degeneration (AMD) Therapeutics Market Forecast
10.4 Europe Age-Related Macular Degeneration (AMD) Therapeutics Forecast by Country (2025-2030)
10.4.1 Germany Age-Related Macular Degeneration (AMD) Therapeutics Market Forecast
10.4.2 France Age-Related Macular Degeneration (AMD) Therapeutics Market Forecast
10.4.3 UK Age-Related Macular Degeneration (AMD) Therapeutics Market Forecast
10.4.4 Italy Age-Related Macular Degeneration (AMD) Therapeutics Market Forecast
10.4.5 Russia Age-Related Macular Degeneration (AMD) Therapeutics Market Forecast
10.5 Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Forecast by Region (2025-2030)
10.5.1 Egypt Age-Related Macular Degeneration (AMD) Therapeutics Market Forecast
10.5.2 South Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Forecast
10.5.3 Israel Age-Related Macular Degeneration (AMD) Therapeutics Market Forecast
10.5.4 Turkey Age-Related Macular Degeneration (AMD) Therapeutics Market Forecast
10.5.5 GCC Countries Age-Related Macular Degeneration (AMD) Therapeutics Market Forecast
10.6 Global Age-Related Macular Degeneration (AMD) Therapeutics Forecast by Type (2025-2030)
10.7 Global Age-Related Macular Degeneration (AMD) Therapeutics Forecast by Application (2025-2030)
11 KEY PLAYERS ANALYSIS
11.1 Amgen Inc.
11.1.1 Amgen Inc. Company Information
11.1.2 Amgen Inc. Age-Related Macular Degeneration (AMD) Therapeutics Product Offered
11.1.3 Amgen Inc. Age-Related Macular Degeneration (AMD) Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 Amgen Inc. Main Business Overview
11.1.5 Amgen Inc. Latest Developments
11.2 Bausch Health Companies, Inc.
11.2.1 Bausch Health Companies, Inc. Company Information
11.2.2 Bausch Health Companies, Inc. Age-Related Macular Degeneration (AMD) Therapeutics Product Offered
11.2.3 Bausch Health Companies, Inc. Age-Related Macular Degeneration (AMD) Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 Bausch Health Companies, Inc. Main Business Overview
11.2.5 Bausch Health Companies, Inc. Latest Developments
11.3 F. Hoffmann-La Roche Ltd.
11.3.1 F. Hoffmann-La Roche Ltd. Company Information
11.3.2 F. Hoffmann-La Roche Ltd. Age-Related Macular Degeneration (AMD) Therapeutics Product Offered
11.3.3 F. Hoffmann-La Roche Ltd. Age-Related Macular Degeneration (AMD) Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 F. Hoffmann-La Roche Ltd. Main Business Overview
11.3.5 F. Hoffmann-La Roche Ltd. Latest Developments
11.4 Novartis AG
11.4.1 Novartis AG Company Information
11.4.2 Novartis AG Age-Related Macular Degeneration (AMD) Therapeutics Product Offered
11.4.3 Novartis AG Age-Related Macular Degeneration (AMD) Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 Novartis AG Main Business Overview
11.4.5 Novartis AG Latest Developments
11.5 Regeneron Pharmaceuticals Inc.
11.5.1 Regeneron Pharmaceuticals Inc. Company Information
11.5.2 Regeneron Pharmaceuticals Inc. Age-Related Macular Degeneration (AMD) Therapeutics Product Offered
11.5.3 Regeneron Pharmaceuticals Inc. Age-Related Macular Degeneration (AMD) Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 Regeneron Pharmaceuticals Inc. Main Business Overview
11.5.5 Regeneron Pharmaceuticals Inc. Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size 2019-2030
2.1.2 Age-Related Macular Degeneration (AMD) Therapeutics Market Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Age-Related Macular Degeneration (AMD) Therapeutics Segment by Type
2.2.1 Wet AMD
2.2.2 Dry AMD
2.3 Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type
2.3.1 Age-Related Macular Degeneration (AMD) Therapeutics Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size Market Share by Type (2019-2024)
2.4 Age-Related Macular Degeneration (AMD) Therapeutics Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Research Institute
2.4.4 Other
2.5 Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application
2.5.1 Age-Related Macular Degeneration (AMD) Therapeutics Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size Market Share by Application (2019-2024)
3 AGE-RELATED MACULAR DEGENERATION (AMD) THERAPEUTICS MARKET SIZE BY PLAYER
3.1 Age-Related Macular Degeneration (AMD) Therapeutics Market Size Market Share by Players
3.1.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Players (2019-2024)
3.1.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 AGE-RELATED MACULAR DEGENERATION (AMD) THERAPEUTICS BY REGIONS
4.1 Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Regions (2019-2024)
4.2 Americas Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth (2019-2024)
4.3 APAC Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth (2019-2024)
4.4 Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth (2019-2024)
4.5 Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth (2019-2024)
5 AMERICAS
5.1 Americas Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country (2019-2024)
5.2 Americas Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2019-2024)
5.3 Americas Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Region (2019-2024)
6.2 APAC Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2019-2024)
6.3 APAC Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Age-Related Macular Degeneration (AMD) Therapeutics by Country (2019-2024)
7.2 Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2019-2024)
7.3 Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics by Region (2019-2024)
8.2 Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2019-2024)
8.3 Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) THERAPEUTICS MARKET FORECAST
10.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Forecast by Regions (2025-2030)
10.1.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Forecast by Regions (2025-2030)
10.1.2 Americas Age-Related Macular Degeneration (AMD) Therapeutics Forecast
10.1.3 APAC Age-Related Macular Degeneration (AMD) Therapeutics Forecast
10.1.4 Europe Age-Related Macular Degeneration (AMD) Therapeutics Forecast
10.1.5 Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Forecast
10.2 Americas Age-Related Macular Degeneration (AMD) Therapeutics Forecast by Country (2025-2030)
10.2.1 United States Age-Related Macular Degeneration (AMD) Therapeutics Market Forecast
10.2.2 Canada Age-Related Macular Degeneration (AMD) Therapeutics Market Forecast
10.2.3 Mexico Age-Related Macular Degeneration (AMD) Therapeutics Market Forecast
10.2.4 Brazil Age-Related Macular Degeneration (AMD) Therapeutics Market Forecast
10.3 APAC Age-Related Macular Degeneration (AMD) Therapeutics Forecast by Region (2025-2030)
10.3.1 China Age-Related Macular Degeneration (AMD) Therapeutics Market Forecast
10.3.2 Japan Age-Related Macular Degeneration (AMD) Therapeutics Market Forecast
10.3.3 Korea Age-Related Macular Degeneration (AMD) Therapeutics Market Forecast
10.3.4 Southeast Asia Age-Related Macular Degeneration (AMD) Therapeutics Market Forecast
10.3.5 India Age-Related Macular Degeneration (AMD) Therapeutics Market Forecast
10.3.6 Australia Age-Related Macular Degeneration (AMD) Therapeutics Market Forecast
10.4 Europe Age-Related Macular Degeneration (AMD) Therapeutics Forecast by Country (2025-2030)
10.4.1 Germany Age-Related Macular Degeneration (AMD) Therapeutics Market Forecast
10.4.2 France Age-Related Macular Degeneration (AMD) Therapeutics Market Forecast
10.4.3 UK Age-Related Macular Degeneration (AMD) Therapeutics Market Forecast
10.4.4 Italy Age-Related Macular Degeneration (AMD) Therapeutics Market Forecast
10.4.5 Russia Age-Related Macular Degeneration (AMD) Therapeutics Market Forecast
10.5 Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Forecast by Region (2025-2030)
10.5.1 Egypt Age-Related Macular Degeneration (AMD) Therapeutics Market Forecast
10.5.2 South Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Forecast
10.5.3 Israel Age-Related Macular Degeneration (AMD) Therapeutics Market Forecast
10.5.4 Turkey Age-Related Macular Degeneration (AMD) Therapeutics Market Forecast
10.5.5 GCC Countries Age-Related Macular Degeneration (AMD) Therapeutics Market Forecast
10.6 Global Age-Related Macular Degeneration (AMD) Therapeutics Forecast by Type (2025-2030)
10.7 Global Age-Related Macular Degeneration (AMD) Therapeutics Forecast by Application (2025-2030)
11 KEY PLAYERS ANALYSIS
11.1 Amgen Inc.
11.1.1 Amgen Inc. Company Information
11.1.2 Amgen Inc. Age-Related Macular Degeneration (AMD) Therapeutics Product Offered
11.1.3 Amgen Inc. Age-Related Macular Degeneration (AMD) Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 Amgen Inc. Main Business Overview
11.1.5 Amgen Inc. Latest Developments
11.2 Bausch Health Companies, Inc.
11.2.1 Bausch Health Companies, Inc. Company Information
11.2.2 Bausch Health Companies, Inc. Age-Related Macular Degeneration (AMD) Therapeutics Product Offered
11.2.3 Bausch Health Companies, Inc. Age-Related Macular Degeneration (AMD) Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 Bausch Health Companies, Inc. Main Business Overview
11.2.5 Bausch Health Companies, Inc. Latest Developments
11.3 F. Hoffmann-La Roche Ltd.
11.3.1 F. Hoffmann-La Roche Ltd. Company Information
11.3.2 F. Hoffmann-La Roche Ltd. Age-Related Macular Degeneration (AMD) Therapeutics Product Offered
11.3.3 F. Hoffmann-La Roche Ltd. Age-Related Macular Degeneration (AMD) Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 F. Hoffmann-La Roche Ltd. Main Business Overview
11.3.5 F. Hoffmann-La Roche Ltd. Latest Developments
11.4 Novartis AG
11.4.1 Novartis AG Company Information
11.4.2 Novartis AG Age-Related Macular Degeneration (AMD) Therapeutics Product Offered
11.4.3 Novartis AG Age-Related Macular Degeneration (AMD) Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 Novartis AG Main Business Overview
11.4.5 Novartis AG Latest Developments
11.5 Regeneron Pharmaceuticals Inc.
11.5.1 Regeneron Pharmaceuticals Inc. Company Information
11.5.2 Regeneron Pharmaceuticals Inc. Age-Related Macular Degeneration (AMD) Therapeutics Product Offered
11.5.3 Regeneron Pharmaceuticals Inc. Age-Related Macular Degeneration (AMD) Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 Regeneron Pharmaceuticals Inc. Main Business Overview
11.5.5 Regeneron Pharmaceuticals Inc. Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Age-Related Macular Degeneration (AMD) Therapeutics Market Size CAGR by Region (2019 VS 2023 VS 2030) & ($ Millions)
Table 2. Major Players of Wet AMD
Table 3. Major Players of Dry AMD
Table 4. Age-Related Macular Degeneration (AMD) Therapeutics Market Size CAGR by Type (2019 VS 2023 VS 2030) & ($ Millions)
Table 5. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2019-2024) & ($ Millions)
Table 6. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size Market Share by Type (2019-2024)
Table 7. Age-Related Macular Degeneration (AMD) Therapeutics Market Size CAGR by Application (2019 VS 2023 VS 2030) & ($ Millions)
Table 8. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2019-2024) & ($ Millions)
Table 9. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size Market Share by Application (2019-2024)
Table 10. Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Players (2019-2024) & ($ Millions)
Table 11. Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share by Player (2019-2024)
Table 12. Age-Related Macular Degeneration (AMD) Therapeutics Key Players Head office and Products Offered
Table 13. Age-Related Macular Degeneration (AMD) Therapeutics Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
Table 14. New Products and Potential Entrants
Table 15. Mergers & Acquisitions, Expansion
Table 16. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Regions 2019-2024 & ($ Millions)
Table 17. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size Market Share by Regions (2019-2024)
Table 18. Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Country/Region (2019-2024) & ($ millions)
Table 19. Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share by Country/Region (2019-2024)
Table 20. Americas Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country (2019-2024) & ($ Millions)
Table 21. Americas Age-Related Macular Degeneration (AMD) Therapeutics Market Size Market Share by Country (2019-2024)
Table 22. Americas Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2019-2024) & ($ Millions)
Table 23. Americas Age-Related Macular Degeneration (AMD) Therapeutics Market Size Market Share by Type (2019-2024)
Table 24. Americas Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2019-2024) & ($ Millions)
Table 25. Americas Age-Related Macular Degeneration (AMD) Therapeutics Market Size Market Share by Application (2019-2024)
Table 26. APAC Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Region (2019-2024) & ($ Millions)
Table 27. APAC Age-Related Macular Degeneration (AMD) Therapeutics Market Size Market Share by Region (2019-2024)
Table 28. APAC Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2019-2024) & ($ Millions)
Table 29. APAC Age-Related Macular Degeneration (AMD) Therapeutics Market Size Market Share by Type (2019-2024)
Table 30. APAC Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2019-2024) & ($ Millions)
Table 31. APAC Age-Related Macular Degeneration (AMD) Therapeutics Market Size Market Share by Application (2019-2024)
Table 32. Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country (2019-2024) & ($ Millions)
Table 33. Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size Market Share by Country (2019-2024)
Table 34. Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2019-2024) & ($ Millions)
Table 35. Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size Market Share by Type (2019-2024)
Table 36. Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2019-2024) & ($ Millions)
Table 37. Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size Market Share by Application (2019-2024)
Table 38. Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Region (2019-2024) & ($ Millions)
Table 39. Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size Market Share by Region (2019-2024)
Table 40. Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2019-2024) & ($ Millions)
Table 41. Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size Market Share by Type (2019-2024)
Table 42. Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2019-2024) & ($ Millions)
Table 43. Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size Market Share by Application (2019-2024)
Table 44. Key Market Drivers & Growth Opportunities of Age-Related Macular Degeneration (AMD) Therapeutics
Table 45. Key Market Challenges & Risks of Age-Related Macular Degeneration (AMD) Therapeutics
Table 46. Key Industry Trends of Age-Related Macular Degeneration (AMD) Therapeutics
Table 47. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size Forecast by Regions (2025-2030) & ($ Millions)
Table 48. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size Market Share Forecast by Regions (2025-2030)
Table 49. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size Forecast by Type (2025-2030) & ($ Millions)
Table 50. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size Forecast by Application (2025-2030) & ($ Millions)
Table 51. Amgen Inc. Details, Company Type, Age-Related Macular Degeneration (AMD) Therapeutics Area Served and Its Competitors
Table 52. Amgen Inc. Age-Related Macular Degeneration (AMD) Therapeutics Product Offered
Table 53. Amgen Inc. Age-Related Macular Degeneration (AMD) Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 54. Amgen Inc. Main Business
Table 55. Amgen Inc. Latest Developments
Table 56. Bausch Health Companies, Inc. Details, Company Type, Age-Related Macular Degeneration (AMD) Therapeutics Area Served and Its Competitors
Table 57. Bausch Health Companies, Inc. Age-Related Macular Degeneration (AMD) Therapeutics Product Offered
Table 58. Bausch Health Companies, Inc. Main Business
Table 59. Bausch Health Companies, Inc. Age-Related Macular Degeneration (AMD) Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 60. Bausch Health Companies, Inc. Latest Developments
Table 61. F. Hoffmann-La Roche Ltd. Details, Company Type, Age-Related Macular Degeneration (AMD) Therapeutics Area Served and Its Competitors
Table 62. F. Hoffmann-La Roche Ltd. Age-Related Macular Degeneration (AMD) Therapeutics Product Offered
Table 63. F. Hoffmann-La Roche Ltd. Main Business
Table 64. F. Hoffmann-La Roche Ltd. Age-Related Macular Degeneration (AMD) Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 65. F. Hoffmann-La Roche Ltd. Latest Developments
Table 66. Novartis AG Details, Company Type, Age-Related Macular Degeneration (AMD) Therapeutics Area Served and Its Competitors
Table 67. Novartis AG Age-Related Macular Degeneration (AMD) Therapeutics Product Offered
Table 68. Novartis AG Main Business
Table 69. Novartis AG Age-Related Macular Degeneration (AMD) Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 70. Novartis AG Latest Developments
Table 71. Regeneron Pharmaceuticals Inc. Details, Company Type, Age-Related Macular Degeneration (AMD) Therapeutics Area Served and Its Competitors
Table 72. Regeneron Pharmaceuticals Inc. Age-Related Macular Degeneration (AMD) Therapeutics Product Offered
Table 73. Regeneron Pharmaceuticals Inc. Main Business
Table 74. Regeneron Pharmaceuticals Inc. Age-Related Macular Degeneration (AMD) Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 75. Regeneron Pharmaceuticals Inc. Latest Developments
Table 1. Age-Related Macular Degeneration (AMD) Therapeutics Market Size CAGR by Region (2019 VS 2023 VS 2030) & ($ Millions)
Table 2. Major Players of Wet AMD
Table 3. Major Players of Dry AMD
Table 4. Age-Related Macular Degeneration (AMD) Therapeutics Market Size CAGR by Type (2019 VS 2023 VS 2030) & ($ Millions)
Table 5. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2019-2024) & ($ Millions)
Table 6. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size Market Share by Type (2019-2024)
Table 7. Age-Related Macular Degeneration (AMD) Therapeutics Market Size CAGR by Application (2019 VS 2023 VS 2030) & ($ Millions)
Table 8. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2019-2024) & ($ Millions)
Table 9. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size Market Share by Application (2019-2024)
Table 10. Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Players (2019-2024) & ($ Millions)
Table 11. Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share by Player (2019-2024)
Table 12. Age-Related Macular Degeneration (AMD) Therapeutics Key Players Head office and Products Offered
Table 13. Age-Related Macular Degeneration (AMD) Therapeutics Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
Table 14. New Products and Potential Entrants
Table 15. Mergers & Acquisitions, Expansion
Table 16. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Regions 2019-2024 & ($ Millions)
Table 17. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size Market Share by Regions (2019-2024)
Table 18. Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Country/Region (2019-2024) & ($ millions)
Table 19. Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share by Country/Region (2019-2024)
Table 20. Americas Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country (2019-2024) & ($ Millions)
Table 21. Americas Age-Related Macular Degeneration (AMD) Therapeutics Market Size Market Share by Country (2019-2024)
Table 22. Americas Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2019-2024) & ($ Millions)
Table 23. Americas Age-Related Macular Degeneration (AMD) Therapeutics Market Size Market Share by Type (2019-2024)
Table 24. Americas Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2019-2024) & ($ Millions)
Table 25. Americas Age-Related Macular Degeneration (AMD) Therapeutics Market Size Market Share by Application (2019-2024)
Table 26. APAC Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Region (2019-2024) & ($ Millions)
Table 27. APAC Age-Related Macular Degeneration (AMD) Therapeutics Market Size Market Share by Region (2019-2024)
Table 28. APAC Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2019-2024) & ($ Millions)
Table 29. APAC Age-Related Macular Degeneration (AMD) Therapeutics Market Size Market Share by Type (2019-2024)
Table 30. APAC Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2019-2024) & ($ Millions)
Table 31. APAC Age-Related Macular Degeneration (AMD) Therapeutics Market Size Market Share by Application (2019-2024)
Table 32. Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country (2019-2024) & ($ Millions)
Table 33. Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size Market Share by Country (2019-2024)
Table 34. Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2019-2024) & ($ Millions)
Table 35. Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size Market Share by Type (2019-2024)
Table 36. Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2019-2024) & ($ Millions)
Table 37. Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size Market Share by Application (2019-2024)
Table 38. Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Region (2019-2024) & ($ Millions)
Table 39. Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size Market Share by Region (2019-2024)
Table 40. Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2019-2024) & ($ Millions)
Table 41. Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size Market Share by Type (2019-2024)
Table 42. Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2019-2024) & ($ Millions)
Table 43. Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size Market Share by Application (2019-2024)
Table 44. Key Market Drivers & Growth Opportunities of Age-Related Macular Degeneration (AMD) Therapeutics
Table 45. Key Market Challenges & Risks of Age-Related Macular Degeneration (AMD) Therapeutics
Table 46. Key Industry Trends of Age-Related Macular Degeneration (AMD) Therapeutics
Table 47. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size Forecast by Regions (2025-2030) & ($ Millions)
Table 48. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size Market Share Forecast by Regions (2025-2030)
Table 49. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size Forecast by Type (2025-2030) & ($ Millions)
Table 50. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size Forecast by Application (2025-2030) & ($ Millions)
Table 51. Amgen Inc. Details, Company Type, Age-Related Macular Degeneration (AMD) Therapeutics Area Served and Its Competitors
Table 52. Amgen Inc. Age-Related Macular Degeneration (AMD) Therapeutics Product Offered
Table 53. Amgen Inc. Age-Related Macular Degeneration (AMD) Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 54. Amgen Inc. Main Business
Table 55. Amgen Inc. Latest Developments
Table 56. Bausch Health Companies, Inc. Details, Company Type, Age-Related Macular Degeneration (AMD) Therapeutics Area Served and Its Competitors
Table 57. Bausch Health Companies, Inc. Age-Related Macular Degeneration (AMD) Therapeutics Product Offered
Table 58. Bausch Health Companies, Inc. Main Business
Table 59. Bausch Health Companies, Inc. Age-Related Macular Degeneration (AMD) Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 60. Bausch Health Companies, Inc. Latest Developments
Table 61. F. Hoffmann-La Roche Ltd. Details, Company Type, Age-Related Macular Degeneration (AMD) Therapeutics Area Served and Its Competitors
Table 62. F. Hoffmann-La Roche Ltd. Age-Related Macular Degeneration (AMD) Therapeutics Product Offered
Table 63. F. Hoffmann-La Roche Ltd. Main Business
Table 64. F. Hoffmann-La Roche Ltd. Age-Related Macular Degeneration (AMD) Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 65. F. Hoffmann-La Roche Ltd. Latest Developments
Table 66. Novartis AG Details, Company Type, Age-Related Macular Degeneration (AMD) Therapeutics Area Served and Its Competitors
Table 67. Novartis AG Age-Related Macular Degeneration (AMD) Therapeutics Product Offered
Table 68. Novartis AG Main Business
Table 69. Novartis AG Age-Related Macular Degeneration (AMD) Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 70. Novartis AG Latest Developments
Table 71. Regeneron Pharmaceuticals Inc. Details, Company Type, Age-Related Macular Degeneration (AMD) Therapeutics Area Served and Its Competitors
Table 72. Regeneron Pharmaceuticals Inc. Age-Related Macular Degeneration (AMD) Therapeutics Product Offered
Table 73. Regeneron Pharmaceuticals Inc. Main Business
Table 74. Regeneron Pharmaceuticals Inc. Age-Related Macular Degeneration (AMD) Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 75. Regeneron Pharmaceuticals Inc. Latest Developments
LIST OF FIGURES
Figure 1. Age-Related Macular Degeneration (AMD) Therapeutics Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth Rate 2019-2030 ($ Millions)
Figure 6. Age-Related Macular Degeneration (AMD) Therapeutics Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 7. Age-Related Macular Degeneration (AMD) Therapeutics Sales Market Share by Country/Region (2023)
Figure 8. Age-Related Macular Degeneration (AMD) Therapeutics Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 9. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size Market Share by Type in 2023
Figure 10. Age-Related Macular Degeneration (AMD) Therapeutics in Hospital
Figure 11. Global Age-Related Macular Degeneration (AMD) Therapeutics Market: Hospital (2019-2024) & ($ Millions)
Figure 12. Age-Related Macular Degeneration (AMD) Therapeutics in Clinic
Figure 13. Global Age-Related Macular Degeneration (AMD) Therapeutics Market: Clinic (2019-2024) & ($ Millions)
Figure 14. Age-Related Macular Degeneration (AMD) Therapeutics in Research Institute
Figure 15. Global Age-Related Macular Degeneration (AMD) Therapeutics Market: Research Institute (2019-2024) & ($ Millions)
Figure 16. Age-Related Macular Degeneration (AMD) Therapeutics in Other
Figure 17. Global Age-Related Macular Degeneration (AMD) Therapeutics Market: Other (2019-2024) & ($ Millions)
Figure 18. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size Market Share by Application in 2023
Figure 19. Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share by Player in 2023
Figure 20. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size Market Share by Regions (2019-2024)
Figure 21. Americas Age-Related Macular Degeneration (AMD) Therapeutics Market Size 2019-2024 ($ Millions)
Figure 22. APAC Age-Related Macular Degeneration (AMD) Therapeutics Market Size 2019-2024 ($ Millions)
Figure 23. Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size 2019-2024 ($ Millions)
Figure 24. Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size 2019-2024 ($ Millions)
Figure 25. Americas Age-Related Macular Degeneration (AMD) Therapeutics Value Market Share by Country in 2023
Figure 26. United States Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 27. Canada Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 28. Mexico Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 29. Brazil Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 30. APAC Age-Related Macular Degeneration (AMD) Therapeutics Market Size Market Share by Region in 2023
Figure 31. APAC Age-Related Macular Degeneration (AMD) Therapeutics Market Size Market Share by Type in 2023
Figure 32. APAC Age-Related Macular Degeneration (AMD) Therapeutics Market Size Market Share by Application in 2023
Figure 33. China Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 34. Japan Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 35. Korea Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 36. Southeast Asia Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 37. India Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 38. Australia Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 39. Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size Market Share by Country in 2023
Figure 40. Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size Market Share by Type (2019-2024)
Figure 41. Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size Market Share by Application (2019-2024)
Figure 42. Germany Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 43. France Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 44. UK Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 45. Italy Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 46. Russia Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 47. Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size Market Share by Region (2019-2024)
Figure 48. Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size Market Share by Type (2019-2024)
Figure 49. Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size Market Share by Application (2019-2024)
Figure 50. Egypt Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 51. South Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 52. Israel Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 53. Turkey Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 54. GCC Country Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 55. Americas Age-Related Macular Degeneration (AMD) Therapeutics Market Size 2025-2030 ($ Millions)
Figure 56. APAC Age-Related Macular Degeneration (AMD) Therapeutics Market Size 2025-2030 ($ Millions)
Figure 57. Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size 2025-2030 ($ Millions)
Figure 58. Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size 2025-2030 ($ Millions)
Figure 59. United States Age-Related Macular Degeneration (AMD) Therapeutics Market Size 2025-2030 ($ Millions)
Figure 60. Canada Age-Related Macular Degeneration (AMD) Therapeutics Market Size 2025-2030 ($ Millions)
Figure 61. Mexico Age-Related Macular Degeneration (AMD) Therapeutics Market Size 2025-2030 ($ Millions)
Figure 62. Brazil Age-Related Macular Degeneration (AMD) Therapeutics Market Size 2025-2030 ($ Millions)
Figure 63. China Age-Related Macular Degeneration (AMD) Therapeutics Market Size 2025-2030 ($ Millions)
Figure 64. Japan Age-Related Macular Degeneration (AMD) Therapeutics Market Size 2025-2030 ($ Millions)
Figure 65. Korea Age-Related Macular Degeneration (AMD) Therapeutics Market Size 2025-2030 ($ Millions)
Figure 66. Southeast Asia Age-Related Macular Degeneration (AMD) Therapeutics Market Size 2025-2030 ($ Millions)
Figure 67. India Age-Related Macular Degeneration (AMD) Therapeutics Market Size 2025-2030 ($ Millions)
Figure 68. Australia Age-Related Macular Degeneration (AMD) Therapeutics Market Size 2025-2030 ($ Millions)
Figure 69. Germany Age-Related Macular Degeneration (AMD) Therapeutics Market Size 2025-2030 ($ Millions)
Figure 70. France Age-Related Macular Degeneration (AMD) Therapeutics Market Size 2025-2030 ($ Millions)
Figure 71. UK Age-Related Macular Degeneration (AMD) Therapeutics Market Size 2025-2030 ($ Millions)
Figure 72. Italy Age-Related Macular Degeneration (AMD) Therapeutics Market Size 2025-2030 ($ Millions)
Figure 73. Russia Age-Related Macular Degeneration (AMD) Therapeutics Market Size 2025-2030 ($ Millions)
Figure 74. Spain Age-Related Macular Degeneration (AMD) Therapeutics Market Size 2025-2030 ($ Millions)
Figure 75. Egypt Age-Related Macular Degeneration (AMD) Therapeutics Market Size 2025-2030 ($ Millions)
Figure 76. South Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size 2025-2030 ($ Millions)
Figure 77. Israel Age-Related Macular Degeneration (AMD) Therapeutics Market Size 2025-2030 ($ Millions)
Figure 78. Turkey Age-Related Macular Degeneration (AMD) Therapeutics Market Size 2025-2030 ($ Millions)
Figure 79. GCC Countries Age-Related Macular Degeneration (AMD) Therapeutics Market Size 2025-2030 ($ Millions)
Figure 80. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size Market Share Forecast by Type (2025-2030)
Figure 81. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size Market Share Forecast by Application (2025-2030)
Figure 1. Age-Related Macular Degeneration (AMD) Therapeutics Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth Rate 2019-2030 ($ Millions)
Figure 6. Age-Related Macular Degeneration (AMD) Therapeutics Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 7. Age-Related Macular Degeneration (AMD) Therapeutics Sales Market Share by Country/Region (2023)
Figure 8. Age-Related Macular Degeneration (AMD) Therapeutics Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 9. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size Market Share by Type in 2023
Figure 10. Age-Related Macular Degeneration (AMD) Therapeutics in Hospital
Figure 11. Global Age-Related Macular Degeneration (AMD) Therapeutics Market: Hospital (2019-2024) & ($ Millions)
Figure 12. Age-Related Macular Degeneration (AMD) Therapeutics in Clinic
Figure 13. Global Age-Related Macular Degeneration (AMD) Therapeutics Market: Clinic (2019-2024) & ($ Millions)
Figure 14. Age-Related Macular Degeneration (AMD) Therapeutics in Research Institute
Figure 15. Global Age-Related Macular Degeneration (AMD) Therapeutics Market: Research Institute (2019-2024) & ($ Millions)
Figure 16. Age-Related Macular Degeneration (AMD) Therapeutics in Other
Figure 17. Global Age-Related Macular Degeneration (AMD) Therapeutics Market: Other (2019-2024) & ($ Millions)
Figure 18. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size Market Share by Application in 2023
Figure 19. Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share by Player in 2023
Figure 20. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size Market Share by Regions (2019-2024)
Figure 21. Americas Age-Related Macular Degeneration (AMD) Therapeutics Market Size 2019-2024 ($ Millions)
Figure 22. APAC Age-Related Macular Degeneration (AMD) Therapeutics Market Size 2019-2024 ($ Millions)
Figure 23. Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size 2019-2024 ($ Millions)
Figure 24. Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size 2019-2024 ($ Millions)
Figure 25. Americas Age-Related Macular Degeneration (AMD) Therapeutics Value Market Share by Country in 2023
Figure 26. United States Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 27. Canada Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 28. Mexico Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 29. Brazil Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 30. APAC Age-Related Macular Degeneration (AMD) Therapeutics Market Size Market Share by Region in 2023
Figure 31. APAC Age-Related Macular Degeneration (AMD) Therapeutics Market Size Market Share by Type in 2023
Figure 32. APAC Age-Related Macular Degeneration (AMD) Therapeutics Market Size Market Share by Application in 2023
Figure 33. China Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 34. Japan Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 35. Korea Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 36. Southeast Asia Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 37. India Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 38. Australia Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 39. Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size Market Share by Country in 2023
Figure 40. Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size Market Share by Type (2019-2024)
Figure 41. Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size Market Share by Application (2019-2024)
Figure 42. Germany Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 43. France Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 44. UK Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 45. Italy Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 46. Russia Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 47. Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size Market Share by Region (2019-2024)
Figure 48. Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size Market Share by Type (2019-2024)
Figure 49. Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size Market Share by Application (2019-2024)
Figure 50. Egypt Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 51. South Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 52. Israel Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 53. Turkey Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 54. GCC Country Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 55. Americas Age-Related Macular Degeneration (AMD) Therapeutics Market Size 2025-2030 ($ Millions)
Figure 56. APAC Age-Related Macular Degeneration (AMD) Therapeutics Market Size 2025-2030 ($ Millions)
Figure 57. Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size 2025-2030 ($ Millions)
Figure 58. Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size 2025-2030 ($ Millions)
Figure 59. United States Age-Related Macular Degeneration (AMD) Therapeutics Market Size 2025-2030 ($ Millions)
Figure 60. Canada Age-Related Macular Degeneration (AMD) Therapeutics Market Size 2025-2030 ($ Millions)
Figure 61. Mexico Age-Related Macular Degeneration (AMD) Therapeutics Market Size 2025-2030 ($ Millions)
Figure 62. Brazil Age-Related Macular Degeneration (AMD) Therapeutics Market Size 2025-2030 ($ Millions)
Figure 63. China Age-Related Macular Degeneration (AMD) Therapeutics Market Size 2025-2030 ($ Millions)
Figure 64. Japan Age-Related Macular Degeneration (AMD) Therapeutics Market Size 2025-2030 ($ Millions)
Figure 65. Korea Age-Related Macular Degeneration (AMD) Therapeutics Market Size 2025-2030 ($ Millions)
Figure 66. Southeast Asia Age-Related Macular Degeneration (AMD) Therapeutics Market Size 2025-2030 ($ Millions)
Figure 67. India Age-Related Macular Degeneration (AMD) Therapeutics Market Size 2025-2030 ($ Millions)
Figure 68. Australia Age-Related Macular Degeneration (AMD) Therapeutics Market Size 2025-2030 ($ Millions)
Figure 69. Germany Age-Related Macular Degeneration (AMD) Therapeutics Market Size 2025-2030 ($ Millions)
Figure 70. France Age-Related Macular Degeneration (AMD) Therapeutics Market Size 2025-2030 ($ Millions)
Figure 71. UK Age-Related Macular Degeneration (AMD) Therapeutics Market Size 2025-2030 ($ Millions)
Figure 72. Italy Age-Related Macular Degeneration (AMD) Therapeutics Market Size 2025-2030 ($ Millions)
Figure 73. Russia Age-Related Macular Degeneration (AMD) Therapeutics Market Size 2025-2030 ($ Millions)
Figure 74. Spain Age-Related Macular Degeneration (AMD) Therapeutics Market Size 2025-2030 ($ Millions)
Figure 75. Egypt Age-Related Macular Degeneration (AMD) Therapeutics Market Size 2025-2030 ($ Millions)
Figure 76. South Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size 2025-2030 ($ Millions)
Figure 77. Israel Age-Related Macular Degeneration (AMD) Therapeutics Market Size 2025-2030 ($ Millions)
Figure 78. Turkey Age-Related Macular Degeneration (AMD) Therapeutics Market Size 2025-2030 ($ Millions)
Figure 79. GCC Countries Age-Related Macular Degeneration (AMD) Therapeutics Market Size 2025-2030 ($ Millions)
Figure 80. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size Market Share Forecast by Type (2025-2030)
Figure 81. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size Market Share Forecast by Application (2025-2030)
